engleski

Correlation between Standard IHC Method and Herceptest in Detection of HER2/NEU Overexpression in Breast Cancer

Overexpression of the HER2 gene and its protein product could be confirmed using different methods in about 30% of breast cancers. It correlates with a worse prognosis and hormonal therapy resistance. On the other hand, a strong membranous expression of the HER2 oncoprotein presents an immunotherapeutical target for inhibiting a humanized antibody such as a commercially available drug Transtuzumab (Herceptin). To test the reproducibility of the pathohistological scoring we have analyzed HER2 protein expression in twenty-six cases of breast cancer by two comparable IHC methods. Based on the results of our study HER2 protein expression screening using the c-erbB-2 method could be used to find out potential candidates for HerceptTest evaluation . However, HerceptTest is a reliable method for HER2 protein scoring in the paraffin embedded tissue.

HER2/neu; Trastuzumab; breast cancer; HerceptTest; c-erbB-2

nije evidentirano